X

Trial Profile

ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 22 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Patisiran (Primary)
Indications Familial amyloid neuropathy; Transthyretin-related hereditary amyloidosis
Focus Adverse reactions; Therapeutic Use
Acronyms ConTTRibute
Sponsors Alnylam Pharmaceuticals

Most Recent Events

05 Mar 2021 Time frame changed from 1 year prior to enrollment and at routine clinical care visits for up to 10 years to Up to 11 years.
15 Dec 2020 Status changed from not yet recruiting to recruiting.
13 Nov 2020 Planned initiation date changed from 31 Oct 2020 to 30 Nov 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com